Vertex executives warned that Casgevy, its curative treatment for sickle cell disease, would be slow to reach patients. But ...

Vertex Flooring Presents High-Performance SPC Flooring Designed for Stability, Style, and Durability HOLLISTON, MA, ...

What's new? Agentic Vision in Gemini 3 Flash uses a think act observe loop with Python code for visual analysis; available via Gemini API in Google AI Studio and Vertex AI; ...

Agentic Vision combines visual reasoning with code execution to ground answers in visual evidence, delivering a 5% to 10% ...

In mid-January 2026, Bernstein upgraded Vertex Pharmaceuticals to Outperform and UBS initiated coverage with a Buy rating, ...

Some things will remain the same for Vertex five years from now, including its dominance in treating cystic fibrosis (CF). However, the company will likely achieve success in several new markets ...

Vertex delivered a split result this morning that left investors parsing mixed signals. The tax technology provider beat on EPS but missed revenue expectations. Shares were down nearly 10% by the ...

Add Yahoo as a preferred source to see more of our stories on Google. This story was originally published on PharmaVoice. To receive daily news and insights, subscribe to our free daily PharmaVoice ...

Vertex Pharmaceuticals is offering Enlaza Therapeutics more than $2 billion in biobucks through a multitarget drug discovery deal aiming to create new T-cell engagers and small-format drug conjugates.

Bill McColl has 25+ years of experience as a senior producer and writer for TV, radio, and digital media leading teams of anchors, reporters, and editors in creating news broadcasts, covering some of ...

A Vertex Pharmaceuticals drug viewed as a successor to a non-opioid pill that won a landmark FDA approval earlier this year has failed a mid-stage clinical trial, dealing a setback to the company’s ...